Selenium Decreases Thyroid Cancer Cell Growth by Increasing Expression of GADD153 and GADD34
- 29 December 2009
- journal article
- research article
- Published by Informa UK Limited in Nutrition and Cancer
- Vol. 62 (1), 66-73
- https://doi.org/10.1080/01635580903191569
Abstract
Selenium (Se) supplementation is reported to decrease the incidence and total mortality of cancer. Whereas in vitro and in vivo studies have shown a decrease in prostate, lung, and liver cancers, this has not been shown in thyroid cancer. ARO (anaplastic), NPA (BRAF positive papillary), WRO (BRAF negative papillary), and FRO (follicular) cells treated with 150 μM seleno-l-methionine (SM) were assessed for viability at 24, 48, and 72 h. Treated FRO cells were examined for cell cycle using flow cytometry, for apoptosis using terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, and for gene expression using microarray. Genes identified as upregulated were confirmed by real-time PCR (RT-PCR) and proteins by Western blot analysis. SM treatment significantly decreased the proliferation of all cell lines. TUNEL assay showed no evidence of apoptosis, and flow cytometry showed a significant cell-cycle arrest in S (271% increase, P= 0.006) and G2/M (61% increase, P= 0.002) compared to control. Microarray revealed 21 differentially expressed genes with greater than twofold change. A relative overexpression of growth arrest and DNA damage inducible (GADD)34 and GADD153 in treated cells was confirmed with RT-PCR and Western blot. SM inhibits thyroid cancer cell proliferation through a time dependent upregulation of the GADD family of genes and arrest in S and G2/M phases of the cell cycle. This is the first report of selenium induced inhibition of thyroid cancer cell growth.Keywords
This publication has 33 references indexed in Scilit:
- The role of selenium, vitamin C, and zinc in benign thyroid diseases and of selenium in malignant thyroid diseases: Low selenium levels are found in subacute and silent thyroiditis and in papillary and follicular carcinomaBMC Endocrine Disorders, 2008
- Selenomethionine induces p53 mediated cell cycle arrest and apoptosis in human colon cancer cellsCancer Biology & Therapy, 2006
- Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA)The Prostate, 2006
- Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic miceOncogene, 2005
- Molecular Profiling Distinguishes Papillary Carcinoma from Benign Thyroid NodulesJournal of Clinical Endocrinology & Metabolism, 2004
- Copper, Zinc, and Selenium in Whole Blood and Thyroid Tissue of People with Various Thyroid DiseasesBiological Trace Element Research, 2003
- The importance of selenium to human healthThe Lancet, 2000
- Effects of methylselenocysteine on PKC activity, cdk2 phosphorylation and gadd gene expression in synchronized mouse mammary epithelial tumor cellsCancer Letters, 1999
- Inhibitory effect of selenomethionine on the growth of three selected human tumor cell linesCancer Letters, 1998
- Protective role of selenium against hepatitis B virus and primary liver cancer in QidongBiological Trace Element Research, 1997